What is Kymera Therapeutics's other commercial liabilities?

Kymera Therapeutics (KYMR) reported other commercial liabilities of $35.1M in Q1 2026.

How has Kymera Therapeutics's other commercial liabilities changed year-over-year?

Kymera Therapeutics's other commercial liabilities increased by 51.8% year-over-year, from $23.12M to $35.1M.

What is the long-term trend for Kymera Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Kymera Therapeutics's other commercial liabilities has grown at a 32.6% compound annual growth rate (CAGR), from $10.33M to $42.27M.

Kymera Therapeutics KYMR Other Commercial Liabilities

Other Commercial Liabilities at other companies

Johnson & JohnsonJNJ

——

ImmunityBio, Inc.IBRX

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's other commercial liabilities?: Kymera Therapeutics (KYMR) reported other commercial liabilities of $35.1M in Q1 2026.
How has Kymera Therapeutics's other commercial liabilities changed year-over-year?: Kymera Therapeutics's other commercial liabilities increased by 51.8% year-over-year, from $23.12M to $35.1M.
What is the long-term trend for Kymera Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Kymera Therapeutics's other commercial liabilities has grown at a 32.6% compound annual growth rate (CAGR), from $10.33M to $42.27M.